Ki Churl Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ki Churl Chang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Hye Jung Kim
Department of Pharmacology and Institute of Health Sciences, School of Medicine, Gyeongsang National University, Jinju, 52527, Republic of Korea
24 shared publicationsYoung Min Kim
Department of Pharmacology Institute of Health Sciences College of Medicine Gyeongsang National University Jinju Korea
19 shared publicationsEun Jung Park
Department of Pharmacology Institute of Health Sciences College of Medicine Gyeongsang National University Jinju Korea
14 shared publicationsJae Heun Lee
Department of Pharmacology, School of Medicine Gyeongsang National University and Institute of Health Sciences, Jinju, Korea
13 shared publicationsHan Geuk Seo
Department of Pharmacology, School of Medicine, and Institute of Health Sciences, Gyeongsang National University, Jinju 660-290, Korea
8 shared publicationsSang Won Park
Department of Pharmacology and Institute of Health Sciences, School of Medicine, Gyeongsang National University, Jinju 660-751, Republic of Korea; Department of Convergence Medical Science (BK21 Plus), Gyeongsang National University, Jinju 660-751, Republic of Korea
8 shared publications
Latest Publications
- Open Access
- 5 June 2018
- Published by Wiley in FEBS Open Bio
- Vol. 8 (7) , 1119-1126
Degradation of histone deacetylase 4 via the TLR4/JAK/STAT1 signaling pathway promotes the acetylation of high mobility group box 1 (HMGB1) in lipopolysaccharide‐activated macrophages
High mobility group box 1 (HMGB1) has been proposed as crucial in the pathogenesis of many diseases including sepsis. Acetylation of HMGB1 prevents its entry into the nucleus and leads to its secretion from the cell where it can trigger inflammation. We hypothesized that histone deacetylase 4 (HDAC4) controls the acetylation of HMGB1 in lipopolysaccharide (LPS)‐stimulated RAW264.7 cells via the janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. The results showed that LPS treatment promoted the degradation of HDAC4 in a proteasome‐dependent manner, which led to HMGB1 acetylation. In LPS‐activated RAW264.7 cells, treatment with TAK‐242 (a toll like receptor 4 inhibitor) and pyridone 6 (a JAK inhibitor) significantly inhibited HDAC4 degradation and acetylation of HMGB1, and thus prevented secretion of HMGB1. Decreased phosphorylation of STAT1 was also observed. Interestingly, HDAC4 overexpression significantly prevented the acetylation and secretion of HMGB1 in both RAW264.7 cells and isolated murine peritoneal macrophages. We conclude that HDAC4 might be a useful target for the treatment of sepsis.
- 5 June 2018
- Published by Wiley in FEBS Open Bio
- Vol. 8 (7) , 1119-1126
Open AccessDegradation of histone deacetylase 4 via the TLR4/JAK/STAT1 signaling pathway promotes the acetylation of high mobility group box 1 (HMGB1) in lipopolysaccharide‐activated macrophages
High mobility group box 1 (HMGB1) has been proposed as crucial in the pathogenesis of many diseases including sepsis. Acetylation of HMGB1 prevents its entry into the nucleus and leads to its secretion from the cell where it can trigger inflammation. We hypothesized that histone deacetylase 4 (HDAC4) controls the acetylation of HMGB1 in lipopolysaccharide (LPS)‐stimulated RAW264.7 cells via the janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. The results showed that LPS treatment promoted the degradation of HDAC4 in a proteasome‐dependent manner, which led to HMGB1 acetylation. In LPS‐activated RAW264.7 cells, treatment with TAK‐242 (a toll like receptor 4 inhibitor) and pyridone 6 (a JAK inhibitor) significantly inhibited HDAC4 degradation and acetylation of HMGB1, and thus prevented secretion of HMGB1. Decreased phosphorylation of STAT1 was also observed. Interestingly, HDAC4 overexpression significantly prevented the acetylation and secretion of HMGB1 in both RAW264.7 cells and isolated murine peritoneal macrophages. We conclude that HDAC4 might be a useful target for the treatment of sepsis.
- 1 June 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 501 (1) , 73-79
Sirt1 S-nitrosylation induces acetylation of HMGB1 in LPS-activated RAW264.7 cells and endotoxemic mice
- 1 June 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 501 (1) , 73-79
Sirt1 S-nitrosylation induces acetylation of HMGB1 in LPS-activated RAW264.7 cells and endotoxemic mice
- 1 March 2018
- Published by Springer Nature in Inflammation Research
- Vol. 67 (5) , 445-453
Luteolin activates ERK1/2- and Ca2+-dependent HO-1 induction that reduces LPS-induced HMGB1, iNOS/NO, and COX-2 expression in RAW264.7 cells and mitigates acute lung injury of endotoxin mice
Although luteolin has shown to have anti-inflammatory action, no report is available whether luteolin inhibits HMGB1 and protects acute lung injury (ALI) in endotoxin rodents. We hypothesized that HO-1 induction by luteolin might play a crucial role for inhibition of pro-inflammatory mediators including HMGB1 through MAPK signaling in LPS-induced RAW264.7 cells, and it ameliorates ALI of endotoxin mice.
- 1 March 2018
- Published by Springer Nature in Inflammation Research
- Vol. 67 (5) , 445-453
Luteolin activates ERK1/2- and Ca2+-dependent HO-1 induction that reduces LPS-induced HMGB1, iNOS/NO, and COX-2 expression in RAW264.7 cells and mitigates acute lung injury of endotoxin mice
Although luteolin has shown to have anti-inflammatory action, no report is available whether luteolin inhibits HMGB1 and protects acute lung injury (ALI) in endotoxin rodents. We hypothesized that HO-1 induction by luteolin might play a crucial role for inhibition of pro-inflammatory mediators including HMGB1 through MAPK signaling in LPS-induced RAW264.7 cells, and it ameliorates ALI of endotoxin mice.
- 1 February 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 86, 48-56
13-Ethylberberine reduces HMGB1 release through AMPK activation in LPS-activated RAW264.7 cells and protects endotoxemic mice from organ damage
- 1 February 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 86, 48-56
13-Ethylberberine reduces HMGB1 release through AMPK activation in LPS-activated RAW264.7 cells and protects endotoxemic mice from organ damage
- 1 August 2015
- Published by Elsevier in Thrombosis Research
- Vol. 136 (2) , 456-464
Cilostazol inhibits HMGB1 release in LPS-activated RAW 264.7 cells and increases the survival of septic mice
- 1 August 2015
- Published by Elsevier in Thrombosis Research
- Vol. 136 (2) , 456-464
Cilostazol inhibits HMGB1 release in LPS-activated RAW 264.7 cells and increases the survival of septic mice
- 1 August 2015
- Published by Elsevier in Atherosclerosis
- Vol. 241 (2) , 615-623
Retinoic acid inhibits tissue factor and HMGB1 via modulation of AMPK activity in TNF-α activated endothelial cells and LPS-injected mice
- 1 August 2015
- Published by Elsevier in Atherosclerosis
- Vol. 241 (2) , 615-623
Retinoic acid inhibits tissue factor and HMGB1 via modulation of AMPK activity in TNF-α activated endothelial cells and LPS-injected mice
- 1 June 2015
- Published by Elsevier in Biochemical Pharmacology
- Vol. 95 (4) , 279-289
Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals
- 1 June 2015
- Published by Elsevier in Biochemical Pharmacology
- Vol. 95 (4) , 279-289
Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals